Subcutaneous immunoglobulins for the treatment of chronic immune-mediated neuropathies
Intravenous immunoglobulins represent an established therapy for the treatment of chronic immune-mediated neuropathies, specifically chronic inflammatory demyelinating polyradiculoneuropathies (CIDP) as well as multifocal motor neuropathies (MMN). For the treatment of antibody deficiency syndroms subcutaneous immunoglobulins (SCIG) represent a mainstay for decades. An emerging body of evidence suggests that SCIG might exhibit clinical efficacy in CIDP and MMN as well. The following article will review the current evidence for clinical effectiveness as well as safety of SCIG for the treatment of immune-mediated neuropathies and will address remaining open questions in this context.
Key words: CIDP, multifocal motor neuropathy, IVIG, SCIG, immune-mediated neuropathies